Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2084-2088

  Jun, Soo Youn ^a   Jung, Gi Mo ^a   Yoon, Seong Jun ^a   Choi, Yun Jaie ^b   Koh, Woo Suk ^c   Moon, Kyoung Sik ^d   Kang, Sang Hyeon ^a  

^a INtRON Biotechnology Inc   (South Korea)

^b Seoul National University   (South Korea)

^c Coretox Consulting ^*  (South Korea)

^d Korea Institute of Toxicology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ENZYME; COMPLEMENT COMPONENT C3; SAL 200; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOPSY; BACTERIOPHAGE; BODY POSTURE; CARDIOVASCULAR FUNCTION; CENTRAL NERVOUS SYSTEM FUNCTION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL DOG; FEMALE; GOOD LABORATORY PRACTICE; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; RESPIRATORY FUNCTION; SINGLE DRUG DOSE; TOXICITY TESTING; VOMITING; WEIGHT CHANGE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; DOGS; ENDOPEPTIDASES; MALE; RATS;

EID: 84896993913     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02232-13     Document Type: Article

References (27)

1. Jun SY, Jung GM, Son JS, Yoon SJ, Choi YJ, Kang SH. 2011. Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob. Agents Chemother. 55:1764-1767. http://dx.doi.org/10.1128/AAC.01097-10.
2. Jun SY, Jung GM, Yoon SJ, Oh MD, Choi YJ, Lee WJ, Kong JC, Seol JG, Kang SH. 2013. Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int. J. Antimicrob. Agents 41:156-161. http://dx.doi.org/10. 1016/j.ijantimicag.2012.10.011.
3. Young I, Wang I, Roof WD. 2000. Phages will out: strategies of host cell lysis. Trends Microbiol. 8:120-128. http://dx.doi.org/10.1016/S0966-842X(00) 01705-4. (Pubitemid 30155487)
4. Young R. 1992. Bacteriophage lysis: mechanism and regulation. Microbiol. Rev. 56:430-481.
5. Loessner MJ. 2005. Bacteriophage endolysins - current state of research and applications. Curr. Opin. Microbiol. 8:480-487. http://dx.doi.org/10.1016/j. mib.2005.06.002. (Pubitemid 41021911)
6. Loessner MJ, Schneider A, Scherer S. 1995. A new procedure for efficient recovery of DNA, RNA, and proteins from Listeria cells by rapid lysis with a recombinant bacteriophage endolysin. Appl. Environ. Microbiol. 61:1150-1152.
7. Low LY, Yang C, Perego M, Osterman A, Liddington RC. 2005. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J. Biol. Chem. 280:35433-35439. http://dx.doi.org/10.1074/jbc.M502723200. (Pubitemid 41532733)
8. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. 2005. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob. Agents Chemother. 49:4789-4792. http://dx.doi.org/10.1128/AAC.49.11.4789-4792.2005. (Pubitemid 41552621)
9. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. 2005. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J. Bacteriol. 187:7161-7164. http://dx.doi.org/10.1128/ JB.187.20.7161-7164.2005. (Pubitemid 41428894)
10. Yuan Y, Peng Q, Gao M. 2012. Characteristics of a broad lytic spectrum endolysin from phage BtCS33 of Bacillus thuringiensis. BMC Microbiol. 12:297. http://dx.doi.org/10.1186/1471-2180-12-297.
11. Jado I, López R, García E, Fenoll A, Casal J, García P. 2003. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52:967-973. http://dx.doi.org/10.1093/jac/dkg485. (Pubitemid 38008417)
12. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. U. S. A. 98:4107-4112. http://dx.doi.org/10.1073/pnas.061038398. (Pubitemid 32249906)
13. Loeffler JM, Djurkovic S, Fischetti VA. 2003. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect. Immun. 71:6199-6204. http://dx.doi.org/10.1128/IAI.71.11.6199-6204.2003. (Pubitemid 37337675)
14. McCullers JA, Karlström A, Iverson AR, Loeffler JM, Fischetti VA. 2007. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog. 3:e28. http://dx.doi.org/10.1371/journal.ppat.0030028.
15. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. http://dx.doi.org/10.1126/science.1066869. (Pubitemid 33150674)
16. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49:111-117. http://dx.doi.org/10. 1128/AAC.49.1.111-117.2005. (Pubitemid 40065780)
17. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Yagyu K, Muraoka A, Sugai M, Hiramatsu K, Honke K, Matsuzaki S. 2007. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage ΦMR11. J. Infect. Dis. 196:1237-1247. http://dx.doi.org/10.1086/521305. (Pubitemid 47580279)
18. Yoong P, Schuch R, Nelson D, Fischetti VA. 2006. PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis. J. Bacteriol. 188:2711-2714. http://dx.doi.org/10.1128/JB.188.7.2711- 2714.2006.
19. Fenton M, Ross P, McAuliffe O, O'Mahony J, Coffey A. 2010. Recombinant bacteriophage lysins as antibacterials. Bioeng. Bugs 1:9-16. http://dx.doi.org/10.4161/bbug.1.1.9818.
20. Irwin S. 1964. Drug screening and evaluation of new drugs in animals, in Animal and clinical pharmacologic techniques in drug evaluation, p 36-54. In Nodine JM, Siegler PE (ed), Animal and clinical techniques in drug evaluation. Year Book Medical Publishers, Chicago, IL.
21. Chiang AY, Smith WC, Main BW, Sarazan RD. 2004. Statistical power analysis for hemodynamic cardiovascular safety pharmacology studies in beagle dogs. J. Pharmacol. Toxicol. Methods 50:121-130. http://dx.doi.org/10.1016/j. vascn.2004.03.009. (Pubitemid 39286324)
22. Sarazan RD. 1993. Chronically instrumented conscious dog model in cardiovascular toxicology studies. Toxicol. Methods 3:195-211. http://dx.doi.org/10.3109/15376519309044576.
23. Murata K, Baldwin WM 3rd. 2009. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant. Rev. 23:139-150. http://dx.doi.org/10.1016/j.trre.2009. 02.005.
24. Korbelik M, Cecic I. 2008. Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. J. Photochem. Photobiol. B 93:53-59. http://dx.doi.org/10.1016/j.jphotobiol. 2008.04.005.
25. Jackson R. 2000. Serum sickness. J. Cutan. Med. Surg. 4:223-225.
26. Huang CY, Hung DZ, Chen WK. 2010. Antivenin-related serum sickness. J. Chin. Med. Assoc. 73:540-542. http://dx.doi.org/10.1016/S1726-4901(10)70117-9.
27. Todd DJ, Helfgott SM. 2007. Serum sickness following treatment with rituximab. J. Rheumatol. 34:430-433.